Gosset Ownership
Private
Employees
~5
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
PhagePro General Information
PhagePro’s lead product, ProphaLytic-Vc, has demonstrated promise in preclinical studies as an oral bacteriophage preparation targeting epidemic cholera strains. The company aims to prevent household and community transmission of cholera with a rapidly acting prophylactic treatment. Clinical trials are being prepared but have not yet commenced as of the latest available information.
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Boston, Massachusetts
United States
United States
Drug Pipeline
ProphaLytic-Vc
Pre-clinicalKey Partnerships
Collaborations with external partners for formulation optimization and manufacturing CROs mentioned; specific partner names not disclosed.
PhagePro Funding
No funding data available
To view PhagePro's complete valuation and funding history, request access »